Table 1

Demographics and baseline characteristics

PlaceboPrimary cohortExploratory cohorts
Dapagliflozin morning doseDapagliflozin evening doseDapagliflozin morning dose (A1C ≥ 10.1)
2.5 mg5 mg10 mg2.5 mg5 mg10 mg5 mg10 mg
n756564706768763439
Age (years)52.7 ± 10.353.0 ± 11.752.6 ± 10.950.6 ± 9.9754.3 ± 11.554.5 ± 11.050.7 ± 9.748.3 ± 9.347.9 ± 12.1
Men31 (41.3)36 (55.4)31 (48.4)34 (48.6)29 (43.3)29 (42.6)39 (51.3)24 (70.6)23 (59.0)
Women44 (58.7)29 (44.6)33 (51.6)36 (51.4)38 (56.7)39 (57.4)37 (48.7)10 (29.4)16 (41.0)
A1C (%)7.84 ± 0.877.92 ± 0.907.86 ± 0.948.01 ± 0.967.99 ± 0.997.82 ± 0.917.99 ± 1.0510.82 ± 0.9310.73 ± 0.85
FPG (mg/dl)159.9 ± 42.1164.1 ± 48.0162.2 ± 45.0166.6 ± 41.5160.6 ± 45.9157.0 ± 50.9168.1 ± 57.9231.6 ± 65.1241.2 ± 65.7
Weight (kg)88.8 ± 19.090.8 ± 22.887.6 ± 17.194.2 ± 18.788.3 ± 20.589.2 ± 20.592.1 ± 22.088.7 ± 19.287.5 ± 22.7
BMI (kg/m2)*32.3 ± 5.532.6 ± 5.531.9 ± 4.833.6 ± 5.432.2 ± 5.332.8 ± 5.333.3 ± 5.632.6 ± 4.631.1 ± 5.9
Diabetes duration (years)0.50 (0.10, 3.40)0.50 (0.1, 2.90)0.25 (0.10, 1.40)0.45 (0.10, 3.40)0.20 (0.10, 1.20)0.50 (0.15, 2.20)0.40 (0.10, 2.45)0.65 (0.20, 2.50)1.40 (0.20, 3.50)
  • Data are means ± SD, n (%), or median (quartile 1, quartile 3).

  • *Mean baseline value for patients who have at least one postbaseline BMI measurement.